NUR 600 Topic 4 pharmacology case workup example

Advanced Integrative Concepts: Pathophysiology, Pharmacology and Assessment Grand Canyon University Free custom sample in 24 to 48h

This NUR 600 Topic 4 sample paper weighs three drug classes against one mechanism to choose a disease-modifying drug for Mrs. G., who has preserved-ejection-fraction heart failure and reduced kidney function. It was prepared for GCU NUR 600, Advanced Integrative Concepts: Pathophysiology, Pharmacology and Assessment, catalog code NUR-600, a core course of Grand Canyon University's MSN. Each candidate is described by the step it interrupts. A loop diuretic relieves congestion but does not modify disease. A mineralocorticoid receptor antagonist, from Pitt and colleagues' TOPCAT trial, risks high potassium given reduced kidney function. An SGLT2 inhibitor, after Anker and colleagues and Solomon and colleagues, is chosen. Monitoring is specific to Mrs. G.

CourseNUR 600 Advanced Integrative Concepts: Pathophysiology, Pharmacology and Assessment
TopicTopic 4
Paper typePharmacologic decision analysis
LengthAbout 970 words, 3 pages
FormatAPA 7 student paper
SchoolGrand Canyon University (GCU)
ProgramMSN
UpdatedOctober 2026

Free sample paper for NUR 600 Topic 4

1

Three Classes Against One Mechanism: Choosing a Disease-Modifying Drug for Heart Failure With Preserved Ejection Fraction in a Patient With Reduced Kidney Function

[Author Name]

College of Nursing and Health Care Professions, Grand Canyon University

NUR-600: Advanced Integrative Concepts: Pathophysiology, Pharmacology and Assessment

Topic 4 Assignment

[Instructor Name]

August 27, 2029

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

What this page is doingThe title sets three candidate drug classes against the mechanism established earlier. Each class is described by the step it interrupts rather than by its indication, which makes elimination possible: one treats a consequence rather than the cause, one is removed on the patient rather than the mechanism, and one is chosen. Monitoring is specific to this patient. The patient is a composite.
2

Three Classes Against One Mechanism: Choosing a Disease-Modifying Drug for Heart Failure With Preserved Ejection Fraction in a Patient With Reduced Kidney Function

The Mechanism the Drugs Must Answer

Mrs. R. G., 66, has heart failure with preserved ejection fraction and new atrial fibrillation. Her stiff left ventricle fills only at high pressure; her kidneys hold on to salt and water because they read her circulation as underfilled; the retained fluid and raised pressures produce her breathlessness, orthopnea and edema. Her eGFR is 38, her potassium 5.0 mEq/L on lisinopril, and she has type 2 diabetes. This paper addresses the choice of a drug to change the course of her heart failure; rate control and anticoagulation for atrial fibrillation are decided separately.

Candidate One: A Loop Diuretic

Step interrupted: sodium reabsorption in the thick ascending limb of the loop of Henle, increasing salt and water excretion and lowering filling pressures. A loop diuretic acts downstream of the problem. It removes the fluid that her kidneys retained in response to the underlying mechanism, but it does not change ventricular stiffness, the neurohormonal activation driving retention, or her risk of hospitalization over time; it treats the consequence of a compensation rather than the process producing it. It is still needed now, because she is congested, and the guideline recommends diuretics to relieve congestion in heart failure with preserved ejection fraction (Heidenreich et al., 2022). But it is a symptom treatment, not the disease-modifying choice this workup is asked to make.

Candidate Two: A Mineralocorticoid Receptor Antagonist

Step interrupted: aldosterone's action on the collecting duct and on the heart and vessels, reducing sodium retention and possibly fibrosis. On mechanism, this class is plausible, since aldosterone activation contributes to fluid retention and myocardial stiffening. In a large trial in heart failure with preserved ejection fraction, spironolactone did not significantly reduce the primary composite outcome overall, though it reduced hospitalization for heart failure (Pitt et al., 2014).

It is removed here on the patient rather than on the mechanism: with an eGFR of 38 and a potassium already 5.0 mEq/L on an angiotensin-converting enzyme inhibitor, adding a drug that reduces potassium excretion carries a real risk of dangerous hyperkalemia, and the benefit shown in the trial does not justify that risk in her. If her potassium fell to a safer level with dietary changes, or her kidney function improved, the class could be reconsidered with close monitoring.

Candidate Three: A Sodium-Glucose Cotransporter 2 Inhibitor

Step interrupted: sodium and glucose reabsorption in the proximal tubule, producing a mild osmotic diuresis and natriuresis, with effects on cardiac loading, metabolism and kidney hemodynamics that are still being defined. This class acts on the mechanism in several ways at once: it reduces the sodium and fluid retention that raise filling pressures, and it has been associated with reduced progression of kidney disease.

Unlike the other two, it has trial evidence for changing outcomes in this population. In a large trial, empagliflozin lowered the composite of death from cardiovascular causes or hospital admission for heart failure in patients with heart failure and an ejection fraction above 40 percent, driven mainly by fewer hospitalizations (Anker et al., 2021). Dapagliflozin produced a similar reduction in patients with mildly reduced or preserved ejection fraction (Solomon et al., 2022). Both trials included patients with reduced kidney function and with and without diabetes. The guideline recommends this class for heart failure with preserved ejection fraction to reduce hospitalization and cardiovascular death (Heidenreich et al., 2022). For Mrs. G., it also addresses her diabetes, and it does not raise potassium. It is the chosen class.

What this page is doingEach candidate is described by the step it interrupts, which is what allows the elimination: the diuretic acts downstream on a consequence, the second class is removed on the patient's kidney function and potassium, and the third is chosen on both mechanism and outcome evidence. The highlighted sentence shows a plausible drug removed for this patient rather than for its mechanism.
3

Monitoring Specific to This Patient

Monitoring is chosen for what could go wrong in her, not copied from a label. Her kidney function and potassium are rechecked within two weeks, because this class often causes a small, early fall in the estimated glomerular filtration rate that is expected and usually stabilizes, and the clinician needs to know her new baseline rather than misread it as injury. Her weight, orthostatic blood pressure and symptoms of dizziness are checked at the same visit, because she is also on a diuretic and a second natriuretic drug could cause volume depletion; the diuretic dose may need to fall. Because she has diabetes, she is taught to stop the drug during acute illness with vomiting or poor intake and to seek care if she feels unwell, since ketoacidosis can occur even with normal glucose levels. And because genital fungal infections are the most common adverse effect, she is told what to watch for and that it is treatable. Her glucose-lowering regimen is reviewed so that the added drug does not cause hypoglycemia with any insulin or sulfonylurea she may be taking.

The Defense, With the Rejected Candidates

The choice is defensible because it follows from the mechanism and the patient together. The loop diuretic stays for congestion but is not asked to change her prognosis. The mineralocorticoid receptor antagonist is rejected because her kidneys and potassium make it unsafe for her, not because its mechanism is wrong. The sodium-glucose cotransporter 2 inhibitor is chosen because it acts on the retention driving her symptoms, has outcome evidence in patients like her and fits her other conditions. A defense without rejected candidates would hide whether a choice was made at all.

The choice also sets up what happens next. With congestion relieved by the diuretic and the new drug started, the plan's success will be judged at the follow-up visit by her weight, her breathlessness walking to the mailbox, her orthopnea and her laboratory values. If the diuretic can be reduced once the new drug takes effect, that will be a sign the two are working together; if her kidney function falls beyond the expected early dip, the regimen will be reconsidered before anything else is added.

References

Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Bohm, M., Brunner-La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Pina, I. L., ... Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451-1461. https://doi.org/10.1056/NEJMoa2107038

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895-e1032. https://doi.org/10.1161/CIR.0000000000001063

Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O'Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., ... McKinlay, S. M. (2014). Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine, 370(15), 1383-1392. https://doi.org/10.1056/NEJMoa1313731

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., ... Langkilde, A. M. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), 1089-1098. https://doi.org/10.1056/NEJMoa2206286

Reading the GCU NUR 600 Topic 4 instructions

Topic 4 in NUR-600 asks students to select a pharmacologic treatment and defend the choice. Strong papers describe each candidate drug by the step in the disease mechanism it interrupts, weigh the evidence for each in patients like this one and account for the patient's other conditions, such as kidney function and potassium. Students should choose by mechanism and patient together rather than by indication alone, set monitoring for what could go wrong in this patient rather than copying a label and defend the choice against the rejected candidates. Drug detail should be limited to what the argument needs, with trial evidence cited for each class.

How this NUR 600 Topic 4 example is built

The finished workup never lists drug facts that the mechanism did not ask for. Three candidate classes are set against the process established earlier, and each is described by the step it interrupts rather than by its indication. That framing makes the elimination possible. One class acts upstream of the problem in this patient and would be treating a compensation rather than the cause. A second is plausible on mechanism and removed on the patient instead, because her clearance is reduced and something already on her list competes for the same pathway. The survivor is defended on both grounds at once. Monitoring parameters are chosen from the mechanism, so each one would detect a specific failure, and the workup states which result would send the reasoning back to the second candidate.

NUR 600 Topic 4 rubric: what Excellent looks like

Faculty reward drugs chosen by mechanism and patient together. An Excellent paper describes a loop diuretic, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor by the step each interrupts. Credit goes to weighing Pitt and colleagues' TOPCAT results against potassium risk with reduced kidney function. The rubric values choosing an SGLT2 inhibitor on Anker and colleagues' EMPEROR-Preserved and Solomon and colleagues' DELIVER trials. Strong papers keep the diuretic for congestion. Top marks go to monitoring kidney function and potassium within two weeks.

Common NUR 600 Topic 4 mistakes, and how to avoid them

The commonest failure is a drug profile transcribed at length, accurate and unattached, which answers a question about the agent rather than about this patient. A second loss comes from a choice defended by indication alone, since an approved use names a population and the assignment asked about a mechanism. Papers that never bring the patient's own clearance, list or interactions into the narrowing have written the textbook answer and stopped. Monitoring copied from a general reference is the giveaway that the plan was assembled rather than reasoned, because none of those parameters detects anything specific to this case. Marks also go for a defense with no rejected candidate, which conceals whether a choice was made at all. Dosing detail belongs in practice, not in an academic example.

Get an NUR-600 Topic 4 example written to your instructions

Send the NUR-600 Topic 4 assignment instructions and the rubric your classroom posts, with the case and any drug classes your section names. We write a custom example to those criteria, with candidates placed against the mechanism, narrowed again by the patient herself, and monitoring tied to how the plan could fail, in 24 to 48 hours. The first one is free.

More NUR 600 papers and MSN samples

NUR 600 Topic 4 questions, answered

Why choose an agent by mechanism rather than by indication?

Because an indication describes a population and your patient is one person with a particular process running. Two agents approved for the same condition can act at different points in that process, and only one of them may be touching the step that is actually driving her presentation. Indication tells you what is allowed; mechanism tells you what should work here.

How much drug detail should the paper carry?

Only what the argument uses. Pharmacokinetics matter here because her clearance removed a candidate; a full profile of every property of every agent does not, and it buries the reasoning a grader is looking for. As an academic example it also stays away from specific dosing, which is a clinical decision made with the whole record present.

What makes monitoring parameters defensible?

Each one should detect a particular way this plan could go wrong, traced back to the mechanism. A parameter that would look the same whether the agent is working or failing has been included out of habit. Naming what each measurement is watching for, and how soon it would show, is what separates a monitoring plan from a list.

Where can I find a free NUR 600 Topic 4 sample paper?

The drug choice paper for NUR 600 Topic 4 covers the mechanism the drugs must answer, a loop diuretic, a mineralocorticoid receptor antagonist, an SGLT2 inhibitor, monitoring specific to this patient and the defense with rejected candidates. Your own NUR 600 Topic 4 prompt gets a free paper.

Why choose by mechanism rather than indication in NUR 600 Topic 4?

Because several drugs carry the indication, but only some interrupt the step driving this patient's disease without worsening the other conditions.